GSCDN 2025 3 - 6 June 2025

Etavopivat reduces incidence of vaso-occlusive crises in patients with sickle cell disease: HIBISCUS trial phase 2 results through 52 weeks

Authors :

Julie Kanter¹; Sophia Delicou²; Fuad El Rassi³; Biree Andemariam⁴; Miguel R. Abboud⁵; Marilyn J. Telen⁶; Jessie Githanga⁷; Adlette Inati⁸; Ibrahim Idris⁹; Sunil Navani¹⁰; Eric Wu¹¹; Andrew Eisenberger¹²

Affiliations

View Details Hide Details

Download PDF

Keywords

Rare Blood Disorders

Congress poster

Etavopivat

Search Science Hub

Are you a healthcare professional?

Etavopivat reduces incidence of vaso-occlusive crises in patients with sickle cell disease: HIBISCUS trial phase 2 results through 52 weeks